Paper20183916
Inhaled drug delivery for tuberculosis therapy.
Muttil P and 2 others. Pharm Res, 2009. Cited by 106 papers, by iCite.
Cite this record
ConductScience Library. Inhaled drug delivery for tuberculosis therapy. Papers, record 20183916. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20183916
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Mycobacterium tuberculosis | Major topic |
| Tuberculosis | Major topic |
| Administration, Inhalation | |
| Humans |
Source PubMed
References118
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2564468 | Prevention of Pneumocystis carinii pneumonia by inhaled pentamidine. | Lancet | 1989 | https://conductscience.org/library/papers/2564468 | PubMed |
| 2 | 18419443 | Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. | Clin Infect Dis | 2008 | https://conductscience.org/library/papers/18419443 | PubMed |
| 3 | 16370941 | Aerosolised antibiotics: a critical appraisal of their use. | Expert Opin Drug Deliv | 2006 | https://conductscience.org/library/papers/16370941 | PubMed |
| 4 | 17173225 | Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. | Clin Infect Dis | 2007 | https://conductscience.org/library/papers/17173225 | PubMed |
| 5 | 15608701 | Tuberculosis - metabolism and respiration in the absence of growth. | Nat Rev Microbiol | 2005 | https://conductscience.org/library/papers/15608701 | PubMed |
| 6 | 15680764 | Can laboratory reference strains mirror "real-world" pathogenesis? | Trends Microbiol | 2005 | https://conductscience.org/library/papers/15680764 | PubMed |
| 7 | 16362982 | New insights into the function of granulomas in human tuberculosis. | J Pathol | 2006 | https://conductscience.org/library/papers/16362982 | PubMed |
| 8 | 10985173 | Factors influencing response to treatment of pulmonary tuberculosis. | Acta Med Okayama | 2000 | https://conductscience.org/library/papers/10985173 | PubMed |
| 9 | 12636160 | Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. | Pharm Res | 2003 | https://conductscience.org/library/papers/12636160 | PubMed |
| 10 | 14613962 | Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. | J Antimicrob Chemother | 2003 | https://conductscience.org/library/papers/14613962 | PubMed |
| 11 | 12901560 | Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells. | Expert Rev Vaccines | 2002 | https://conductscience.org/library/papers/12901560 | PubMed |
| 12 | 18658109 | Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. | Am J Respir Crit Care Med | 2008 | https://conductscience.org/library/papers/18658109 | PubMed |
| 13 | 19139288 | Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19139288 | PubMed |
| 14 | 15225870 | Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. | Int J Antimicrob Agents | 2004 | https://conductscience.org/library/papers/15225870 | PubMed |
| 15 | 16441433 | Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. | Cell Microbiol | 2006 | https://conductscience.org/library/papers/16441433 | PubMed |
| 16 | 785420 | Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. | Postgrad Med J | 1975 | https://conductscience.org/library/papers/785420 | PubMed |
| 17 | 16113455 | The lungs as a portal of entry for systemic drug delivery. | Proc Am Thorac Soc | 2004 | https://conductscience.org/library/papers/16113455 | PubMed |
| 18 | 15761077 | Antitubercular inhaled therapy: opportunities, progress and challenges. | J Antimicrob Chemother | 2005 | https://conductscience.org/library/papers/15761077 | PubMed |
| 19 | 7761379 | [Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis]. | Probl Tuberk | 1995 | https://conductscience.org/library/papers/7761379 | PubMed |
| 20 | 13130011 | Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov. | Int J Syst Evol Microbiol | 2003 | https://conductscience.org/library/papers/13130011 | PubMed |
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 106 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42797339 | Engineering of OHet72 Nanocrystals into Nanostructured Microparticles for Pulmonary Delivery of a Novel Antitubercular Drug Candidate. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42797339 | PubMed |
| 42747544 | Inhalable Dry Powders of Antimicrobial Agents in Respiratory Diseases. | Lung | 2026 | https://conductscience.org/library/papers/42747544 | PubMed |
| 40487670 | Inhaled non-viral delivery systems for RNA therapeutics. | Acta Pharm Sin B | 2025 | https://conductscience.org/library/papers/40487670 | PubMed |
| 37590399 | Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations. | Mol Pharm | 2023 | https://conductscience.org/library/papers/37590399 | PubMed |
| 36970149 | Multi-drug loaded eugenol-based nanoemulsions for enhanced anti-mycobacterial activity. | RSC Med Chem | 2023 | https://conductscience.org/library/papers/36970149 | PubMed |
| 36203881 | Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages. | Adv Ther (Weinh) | 2022 | https://conductscience.org/library/papers/36203881 | PubMed |
| 36131190 | A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation. | Drug Deliv Transl Res | 2023 | https://conductscience.org/library/papers/36131190 | PubMed |
| 36114362 | Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment. | Pharm Res | 2022 | https://conductscience.org/library/papers/36114362 | PubMed |
| 35583640 | LipNanoCar Technology - A Versatile and Scalable Technology for the Production of Lipid Nanoparticles. | Adv Exp Med Biol | 2022 | https://conductscience.org/library/papers/35583640 | PubMed |
| 35242137 | The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic. | Front Immunol | 2022 | https://conductscience.org/library/papers/35242137 | PubMed |
| 35112802 | Nano-in-Microparticles for Aerosol Delivery of Antibiotic-Loaded, Fucose-Derivatized, and Macrophage-Targeted Liposomes to Combat Mycobacterial Infections: In Vitro Deposition, Pulmonary Barrier Interactions, and Targeted Delivery. | Adv Healthc Mater | 2022 | https://conductscience.org/library/papers/35112802 | PubMed |
| 34959328 | Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34959328 | PubMed |
| 34041715 | A triple combination 'nano' dry powder inhaler for tuberculosis: in vitro and in vivo pulmonary characterization. | Drug Deliv Transl Res | 2021 | https://conductscience.org/library/papers/34041715 | PubMed |
| 33214909 | The Role of Metallic Nanoparticles in Inhibition of Mycobacterium Tuberculosis and Enhances Phagosome Maturation into the Infected Macrophage. | Oman Med J | 2020 | https://conductscience.org/library/papers/33214909 | PubMed |
| 33049807 | A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers. | Carbohydr Polym | 2020 | https://conductscience.org/library/papers/33049807 | PubMed |
| 31819421 | Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery. | Int J Nanomedicine | 2019 | https://conductscience.org/library/papers/31819421 | PubMed |
| 31650321 | Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs. | Pharm Res | 2019 | https://conductscience.org/library/papers/31650321 | PubMed |
| 31527037 | Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31527037 | PubMed |
| 31321552 | Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. | Pharm Res | 2019 | https://conductscience.org/library/papers/31321552 | PubMed |
| 31152746 | A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy. | J Pharm Sci | 2019 | https://conductscience.org/library/papers/31152746 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20183916
GET https://conductscience.org/api/papers/v1/20183916/references?page=2